

Direct dialkylation of peptide nitriles. Application to the synthesis of 1-aminocyclopropane-1-carboxylic acid (Acc)-containing dipeptides

Andrew R McMath, Dominique Guillaume*, David J Aitken, Henri-Philippe Husson

*Laboratoire de chimie thérapeutique associé au CNRS, Faculté des sciences pharmaceutiques et biologiques,
Université René-Descartes, 4, avenue de l'Observatoire, 75270 Paris cedex 06, France*

(Received 19 September 1996; accepted 2 December 1996)

Summary — Several 1-aminocyclopropane-1-carboxylic acid-containing dipeptides (Acc-CP) have been prepared by regioselective dialkylation of peptoids containing α -aminonitriles as C-terminal residues. Regioselective deprotonation of the aminomethylene center using a strong base and dialkylation by ethylene sulfate lead to cyclopropane peptide nitriles, without inducing racemization on the amino-acid α -position. Subsequent hydrolysis of the nitrile group affords Acc-CP.

cyclopropyl peptide / peptide C-alkylation / cyclopropane amino acid / 1-aminocyclopropanecarbonitrile

Résumé — Substitution directe de peptides nitriles. Application à la synthèse de dipeptides contenant l'acide 1-aminocyclopropane-1-carboxylique. Plusieurs dipeptides contenant l'acide 1-aminocyclopropane-1-carboxylique ont été obtenus par disubstitution régiosélective d'analogues dipeptidiques terminés par un α -aminonitrile. La déprotonation régiosélective de l'aminométhylène par une base forte, et sa disubstitution par le sulfate d'éthylène, conduisent à des peptide-nitriles cyclopropaniques sans entraîner de racémisation en position α de l'acide aminé. L'hydrolyse du groupement nitrile permet d'obtenir les dipeptides avec l'acide 1-aminocyclopropane-1-carboxylique terminal.

peptide cyclopropanique / C-substitution de peptide / acide aminé cyclopropanique / 1-aminocyclopropanecarbonitrile

Introduction

1-Aminocyclopropane-1-carboxylic acid-containing peptides (Acc-CP) [1] constitute a highly valuable class of conformationally constrained analogues for the medicinal chemist because the incorporation of a cyclopropane can induce drastic changes in the peptides properties, ie, stabilization of a specific conformation [2], or modification of the peptides chemical reactivity [3] whilst at the same time introducing only little steric hindrance. Thus, unsurprisingly, a fast-growing number of Acc-CPs have been prepared during the last decade, frequently providing analogues with promising pharmacological activities [4].

Until now, the synthesis of Acc-CP has been achieved, almost exclusively, by step-by-step coupling of the amino acids using liquid or solid phase peptide chemistry [5]. Although Acc is commercially available, the low reactivity of its amino and carboxyl groups [6] often demands the use of long coupling reaction times or of large excesses of reagent compared to non- or mono-substituted amino acids. Clearly, there is still a special need to synthesize these peptides in new ways.

During the course of our studies on the synthesis of cyclopropane amino acids, we have demonstrated the higher reactivity of α -aminonitriles com-


pared to α -aminoesters [7] towards dialkylation with 1,2-dielectrophiles, and among the latter, the unusual efficiency of the 1,2-cyclic sulfates [8]. Combining our methodology with results from Seebach's group on the lack of racemization during the C-alkylation of glycine residues within peptides in the presence of a strong base (lithium diisopropylamide (LDA)) [9], we have designed a new strategy for the synthesis of Acc-CP based on the selective deprotonation of peptides containing aminoacetonitrile as the C-terminal residue with a strong base and using ethylene sulfate as a 1,2-dielectrophile. Subsequent transformation of the nitrile function into an ester is expected to lead directly to the desired Acc-CP (scheme 1). We herein disclose our preliminary results on this procedure.

Results and discussion

Choice of peptide nitriles

Peptides containing α -aminonitrile as the C-terminal residue were first synthesized in 1974 [10] and can be prepared in a similar way to ordinary peptides. In order to define the limits of our strategy, we synthesized four different dipeptide nitriles 1–4, protected in each case

* Correspondence and reprints



Scheme 1. Reagents and conditions: i) LDA (4.4 equiv), HMPA/THF (8.8 equiv), -78°C , 10 min, *n*-BuLi (2.2 equiv), 60 min, ethylene sulfate; ii) a) TFA/ CH_2Cl_2 , b) NaHCO_3 , Z-Cl, c) HCl/MeOH, d) 0.5*N* aqueous HCl.

on the amine function by a *tert*-butoxycarbonyl (Boc) group in analogy with Seebach's results [9, 11] and chosen to determine the following: i) the regioselectivity of the dialkylation reaction (Boc-Gly-NHCH₂CN, **1**); ii) the importance of the steric hindrance at the α -position of the amino acid (Boc-Aib-NHCH₂CN, **2**); iii) the lack of racemization during the dialkylation step (Boc-(L)-Phe-NHCH₂CN, **3**); and iv) the importance of the steric hindrance at the β -position of the amino acid (Boc-(L)-Val-NHCH₂CN, **4**). Compounds **1**–**4** were prepared in 83–90% yields (**2** was prepared in 50% yield) by condensation of the selected *N*-protected amino acid (Boc-Gly, Boc-Aib, Boc-Phe and Boc-Val, respectively) with aminoacetonitrile using liquid phase peptide synthesis.

Evaluation of the regioselectivity of the reaction

We decided first to investigate the difference in reactivity towards cyclopropanation between an aminomethylene center adjacent to a nitrile or a carbonyl function within the same molecule. Double alkylation of **1** by ethylene sulfate 1,3,2-dioxathiolane-2,2-dioxide [8] furnished **1a**, after 5 h, in 55% yield (scheme 1). No trace of the product resulting from the (di)alkylation of the glycine methylene group was detected, thereby establishing the total regioselectivity of the reaction. These results confirm our previous observations [7, 12] and demonstrate once more that in our conditions the methylenes of aminonitriles behave differently to the methylenes neighboring carbonyl functions.

Study of the role of the amino-acid side chain

Having demonstrated the higher reactivity of a methylene adjacent to a nitrile group towards dialkylation, we decided to study the extent of possible steric hindrance close to the alkylation position and, more particularly, the influence of the amino-acid side chain during the reaction. Thus, we studied the case of a dipeptide nitrile composed of an amino acid disubstituted at its α -position. In the conditions described for the synthesis of **1a**, compound **2a** was obtained in 30% yield. Despite the conformational modifications possibly introduced by the Aib residue, we attributed this decrease of reactivity to the steric hindrance of the two methyl

groups, these bulky groups probably precluding, in part, the approach of the dielectrophile.

Evaluation of the lack of epimerization

Aware of the lower reactivity induced by a α -disubstituted amino acid but encouraged by the results observed for the dialkylation of **1**, we decided to prepare a peptide nitrile containing a mono-substituted and optically pure amino acid. This would allow us to evaluate more precisely the role of the substituents at the amino acid α -position, and also provide a chiral compound thereby permitting us to evaluate the degree of epimerization during the course of the alkylation procedure. In order to avoid undesirable reactivity introduced by the amino acid side chain but get reasonable steric hindrance, we chose the (L)-Phe residue as a model amino acid. Hence optically pure **3** was prepared (in 83% yield) then subjected to the conditions used to synthesize **1a**. Compound **3a** was obtained in 50% yield (together with 10% of unreacted **3**). To demonstrate the optical integrity of **3a**, we also synthesized it by condensing Boc-(L)-Phe to 1-aminocyclopropane-1-carbonitrile [13] using conditions similar to those used for the synthesis of **1**–**4** (69% yield). Whatever the chemical pathway used, both compounds displayed similar optical rotation ($[\alpha]_D^{20} = -10.1$ (c 1.8, CH_2Cl_2)). Nevertheless, because of the low value of the optical rotation, we decided to confirm this result. Thus, we prepared a 50:50 mixture of **3a** and its enantiomer **3a'** starting from racemic Boc-Phe and 1-aminocyclopropane-1-carbonitrile. Although we were unable to separate the enantiomers by chiral HPLC, we successfully demonstrated the optical integrity of the *N*-deprotected derivative (TFA, CH_2Cl_2) of **3a** using Alexakis' elegant methodology [14]. This method allowed us to establish the optical integrity of **3a** to be at least 97%.

Further studies on the role of the amino acid side chain

The lack of racemization during the dialkylation procedure is established, and alkylation of monosubstituted peptides gives reasonable yields. We attempted to generalize our method by using Boc-(L)-Val, a common amino acid hindered at its β -position. Dialkylation of **4** (prepared in 84% yield) using our previously defined

conditions led to compound **4a** in 50% yield (together with 8% of unreacted **4**). This yield, similar to that observed for the synthesis of **3a**, showed that the nature of the amino acid alkyl side chain was of little importance for the cyclopropanation reaction.

Synthesis of the dipeptides

Several methods have been reported for the transformation of a nitrile group into an acid or ester function [15]. However, in our case the conditions had to be compatible with the presence of an amide bond and also non-racemizing. Model reactions showed that transformation of the nitrile function of a dipeptide nitrile into an imide could be quantitatively achieved using anhydrous saturated hydrochloric methanol and subsequent hydrolysis of the imide (dilute aqueous HCl) furnishing the corresponding dipeptide. However, since the first step would obviously concomitantly remove a Boc protecting group, we prepared the *Z*-analogues of our initial peptide nitriles and carried out their cyclopropanation using the conditions determined for the Boc derivatives. Unfortunately, these *Z*-derivatives turned out to be much less reactive towards dialkylation than their Boc counterparts. For example, *Z*-Gly-NH-CH₂-CN furnished the expected cyclopropyl peptide analogues in only 20% yield, while *Z*-Aib-NH-CH₂-CN was totally unreactive towards cyclopropanation, longer reaction times or higher temperature (−50 °C) leading only to degradative materials. Model reactions carried out using benzylbromide as a simple electrophile confirmed the higher reactivity of the Boc-protected peptides compared to their *Z*-analogues. Compounds **1**, **3** and **4** were mono-alkylated in 35–70% yields while, in the same conditions, the *Z*-derivatives were alkylated in only 10–25% yields. These results are in accordance with Seebach's hypothesis concerning the possible deprotonation of the *Z*-methylene protons and therefore the difficulty to alkylate amino acids of *Z*-protected peptides [11b]. Thus we returned to the Boc-protected peptide nitriles and prepared the *Z*-protected derivatives in 85–90% overall yield using a two-step deprotection-protection procedure: (a) 20% TFA/CH₂Cl₂; b) NaHCO₃, *Z*-Cl). Hence, we were able to obtain **1b**, **3b**, and **4b** which upon treatment with MeOH/HCl and then 0.5 N HCl aq furnished the expected diprotected peptides **1c**, **3c**, and **4c** respectively (70% yield) which could be isolated and fully characterized.

Conclusion

In summary, this report provides the first example of the synthesis of cyclopropyl peptides using the direct peptide alkylation method [9]. This methodology represents an attractive alternative synthesis for C-terminal cyclopropyl peptides that can be further lengthened. Although for peptides containing α -disubstituted amino acids slightly lower dialkylation yields are observed, in the best cases, this method provides Acc-CP easily and in 50–55% overall yield from an *N*-protected amino acid (three steps). Undeniably, to date, Acc-CPs are still more efficiently prepared by direct condensation of amino acids. However, this method also allows

simple synthesis of conformationally constrained peptide nitrile analogues that are currently considered as peptide surrogates [16]. Moreover, following subsequent chemistry on the nitrile group, Acc-CPs provide an entry to methylketone peptide analogues that are pharmacologically active compounds [17, 18]. Furthermore, the use of substituted sulfates or other 1,2-dielectrophiles should lead to compounds that are more difficult to obtain using coupling peptide chemistry and also provide peptides whose amino acids are unstable. The detailed synthesis of these compounds will be reported shortly [19].

Experimental section

General procedures

Optical rotations were determined with a Perkin-Elmer 214 polarimeter. NMR spectra were recorded on a Bruker AC 300-P spectrometer. Chemical shifts were measured in ppm and given, for the ¹H NMR spectra, relatively to residual solvent traces (CHCl₃, δ = 7.26; DOH, δ = 4.6). For the ¹³C NMR spectra, chemical shifts were given relative to CDCl₃ (δ = 77.7) or for the spectra recorded in D₂O relative to an external reference (dioxane, δ = 66.5). Mass spectra were obtained in chemical ionization mode by direct insertion (ionizing gas NH₃) on a Nermag R10-10 spectrometer. Thin-layer chromatography was performed on aluminium plates precoated with silica gel. Compounds were visualized by heating after dipping in a solution of phosphomolybdic acid (10–20%). Flash column chromatography was performed using Kieselgel 60 (250–450 mesh, SDS). Anhydrous Na₂SO₄ was used to dry organic solutions during workup. Microanalyses were performed at the ICSN, CNRS, Gif-sur-Yvette. Tetrahydrofuran (THF) was distilled under nitrogen from Na/benzophenone and diisopropylamine was distilled under nitrogen from CaH₂ prior use. Hexamethylphosphoramide (HMPA) was distilled and kept over 3 Å molecular sieves.

General procedure for dipeptide nitriles **1–4**

To an ice-cooled solution of *N*-protected amino acid (5 g) and 4-methylmorpholine (2.5 equiv) in dichloromethane (200 mL), was added dicyclohexylcarbodiimide (1 equiv) and 1-hydroxybenzotriazole (1 equiv). After 20 min, the white precipitate of dicyclohexylurea was filtered off and a mixture of aminoacetonitrile hydrochloride (1.1 equiv) and 4-methylmorpholine (2 equiv) in dichloromethane (75 mL) was added. The reaction was stirred for 18 h before being quenched with 1 N HCl (300 mL). The organic phase was collected, washed with brine (2 × 250 mL), dried and concentrated. The residue was chromatographed eluting with cyclohexane/EtOAc (3:1) to yield pure peptide nitriles.

General procedure for cyclopropane dipeptide nitriles **1a–4a**

A solution of dipeptide nitrile (750 mg) in THF was slowly added to a solution of LDA (4.4 equiv) in THF/HMPA (8.8 equiv) prepared under a nitrogen atmosphere at −78 °C. The solution was stirred for 10 min and 2.5 M *n*-BuLi in hexanes (2.2 equiv) was added and the solution stirred for 1 h. A solution of ethylene sulfate (1.2 equiv) in THF was added and the solution stirred for 5 h at −78 °C before being quenched by addition of saturated NH₄Cl. After allowing the solution to warm to rt, the

organic phase was collected and the aqueous phase extracted with dichloromethane. The combined organic phases were dried and concentrated. HMPA was removed from the reaction mixture by a short flash chromatography (cyclohexane/EtOAc, 4:1) and final purification of the cyclopropane peptide nitriles was achieved by flash chromatography (cyclohexane/EtOAc, gradient of increasing polarity).

General procedure for cyclopropane dipeptides 1c, 3c and 4c

Onto a solution of **1b**, **3b** or **4b** in dry methanol at 0 °C, a saturated anhydrous solution of MeOH/HCl was poured. The solution was stirred for 5 h and the volatile material removed under reduced pressure. A 0.5 N aqueous HCl solution was poured on the residue and the solution stirred for 18 h. The solution was extracted with dichloromethane. The organic phase was dried, concentrated and the dipeptides were isolated in pure form by crystallization (EtOAc).

• *{[N-(tert-Butoxycarbonyl)glycyl]amino}acetonitrile 1*

Prepared in 89% yield using the general procedure, mp 112 °C (C₆H₁₂/EtOAc 2:1).

¹H NMR (CDCl₃): 7.05 (br s, 1H), 5.20 (br s, 1H), 4.15 (d, *J* = 5.8 Hz, 2H), 3.80 (d, *J* = 6.0 Hz, 2H).

¹³C NMR (CDCl₃): 170.5, 156.2, 116.1, 80.3, 43.8, 28.2, 27.3.

MS: *m/z* (%) 231 (100) [MNH₄⁺], 214 (40) [MH⁺], 175 (35).
Anal calc for C₉H₁₅N₃O₃: C, 50.68; H, 7.09; N, 19.71. Found: C, 50.52; H, 6.79; N, 19.61.

• *{[N-(tert-Butoxycarbonyl)dimethylglycyl]amino}-acetonitrile 2*

Obtained in 52% yield following the general procedure, mp 120 °C (C₆H₁₂/EtOAc 2:1).

¹H NMR (CDCl₃): 7.45 (t, *J* = 7.5 Hz, 1H), 5.40 (br s, 1H), 4.10 (d, *J* = 7.5 Hz, 2H), 1.35 (s, 6H), 1.30 (s, 9H).

¹³C NMR (CDCl₃): 175.6, 155.0, 116.4, 80.7, 56.6, 28.1, 27.6, 25.4.

MS: *m/z* (%) 259 (100) [MNH₄⁺], 242 (70) [MH⁺], 203 (30), 186 (25).

• *{[N-(tert-Butoxycarbonyl)-L-phenylalanyl]amino}-acetonitrile 3*

Prepared in 83% yield using the general procedure, mp 142 °C (C₆H₁₂/EtOAc 2:1).

[α]_D²⁰ = −11 (*c* = 2.1, CH₂Cl₂).

¹H NMR (CDCl₃): 7.30–7.12 (m, 5H), 6.49 (br s, 1H), 4.91 (br s, 1H), 4.30 (m, 1H), 4.05 (m, 2H), 3.04 (d, *J* = 7.1 Hz, 2H), 1.36 (s, 9H).

¹³C NMR (CDCl₃): 171.8, 155.5, 136.0, 129.2, 128.8, 127.1, 115.5, 81.7, 55.5, 38.1, 28.2, 27.2.

MS: *m/z* (%) 321 (9) [MNH₄⁺], 304 (14) [MH⁺], 248 (86), 204 (100), 120 (39).

Anal calc for C₁₆H₂₁N₃O₃: C, 63.33; H, 6.98; N, 13.86. Found: C, 63.22; H, 6.92; N, 13.87.

• *{[N-(tert-Butoxycarbonyl)-L-valyl]amino}-acetonitrile 4*

Prepared in 84% yield according to the general procedure, mp 93 °C (C₆H₁₂/EtOAc 2:1).

[α]_D²⁰ = −27 (*c* = 1.3, CH₂Cl₂).

¹H NMR (CDCl₃): 7.72 (br s, 1H), 5.40 (d, *J* = 7.1 Hz, 1H), 4.10 (m, 3H), 2.05 (m, 1H), 1.35 (s, 9H), 0.87 (s, 6H).

¹³C NMR (CDCl₃): 172.6, 156.2, 115.9, 80.3, 59.8, 31.0, 28.2, 27.2, 19.1, 18.2.

MS: *m/z* (%) 273 (100) [MNH₄⁺], 256 (5) [MH⁺].

Anal calc for C₁₂H₂₁N₃O₃·1/2H₂O: C, 56.5; H, 8.29; N, 16.46. Found: C, 56.83; H, 8.23; N, 16.43.

• *1-{[N-(tert-Butoxycarbonyl)glycyl]amino}cyclopropane-1-carbonitrile 1a*

Prepared in 55% yield according to the general procedure, mp 151 °C (C₆H₁₂/EtOAc 2:1).

¹H NMR (CDCl₃): 7.25 (m, 5H), 7.02 (s, 1H), 5.53 (br t, 1H), 4.96 (s, 2H), 3.69 (d, *J* = 7.1 Hz, 2H), 1.37 (m, 2H), 1.12 (m, 2H).

¹³C NMR (CDCl₃): 170.5, 156.8, 136.0, 128.5, 128.2, 127.9, 120.0, 67.2, 44.3, 20.2, 16.5.

MS: *m/z* (%) 257 (100) [MNH₄⁺], 240 (14) [MH⁺], 201 (10).
Anal calc for C₁₁H₁₇N₃O₃·1/2H₂O: C, 53.2; H, 7.31; N, 16.93. Found: C, 52.99; H, 6.95; N, 16.93.

• *1-{[N-(tert-Butoxycarbonyl)dimethylglycyl]amino}-cyclopropane-1-carbonitrile 2a*

Obtained in 30% yield following the general procedure, mp 132 °C (C₆H₁₂/EtOAc 2:1).

¹H NMR (CDCl₃): 7.45 (s, 1H), 5.20 (br s, 1H), 1.45 (m, 2H), 1.30 (s, 9H), 1.15 (m, 2H).

¹³C NMR (CDCl₃): 176.0, 154.8, 120.2, 80.7, 56.5, 28.1, 25.2, 16.6.

MS: *m/z* (%) 285 (100) [MNH₄⁺], 268 (10) [MH⁺].

Anal calc for C₁₃H₂₁N₃O₃·1/4 H₂O: C, 57.44; H, 7.97; N, 15.46. Found: C, 57.56; H, 7.72; N, 15.69.

• *1-{[N-(tert-Butoxycarbonyl)-L-phenylalanyl]-amino}cyclopropane-1-carbonitrile 3a*

Obtained in 50% yield according to the general procedure, mp 138 °C (C₆H₁₂/EtOAc 2:1).

[α]_D²⁰ = −10.1 (*c* = 0.2, CH₂Cl₂).

¹H NMR (CDCl₃): 7.25–7.11 (m, 5H), 6.62 (s, 1H), 5.31 (d, *J* = 7.9 Hz, 1H), 4.23 (m, 1H), 2.92 (m, 2H), 1.36 (m, 11H), 0.95 (m, 2H).

¹³C NMR (CDCl₃): 172.4, 155.6, 136.1, 129.2, 128.6, 127.0, 119.6, 80.6, 55.4, 38.5, 28.2, 20.0, 16.5.

MS: *m/z* (%) 347 (23) [MNH₄⁺], 330 (27) [MH⁺], 274 (100), 248 (26), 230 (73), 204 (40), 180 (81), 120 (23), 102 (23).

Anal calc for C₁₈H₂₃N₃O₃: C, 65.62; H, 7.04; N, 12.76. Found: C, 65.44; H, 6.91; N, 12.61.

• *1-{[N-(tert-Butoxycarbonyl)-L-valyl]amino}cyclopropane-1-carbonitrile 4a*

Obtained in 50% yield according to the general procedure, mp 164 °C (C₆H₁₂/EtOAc 2:1).

[α]_D²⁰ = −23 (*c* = 0.2, CH₂Cl₂).

¹H NMR (CDCl₃): 7.91 (s, 1H), 5.55 (d, *J* = 8.2 Hz, 1H), 3.85 (t, *J* = 8.2 Hz, 1H), 1.97 (m, 1H), 1.40 (m, 2H), 1.30 (s, 9H), 1.10 (m, 2H), 0.85 (m, 6H).

¹³C NMR (CDCl₃): 173.5, 156.1, 119.7, 59.5, 31.1, 28.2, 20.1, 19.2, 19.0, 18.2, 16.6, 16.2.

MS: *m/z* (%) 299 (100) [MNH₄⁺], 282 (50) [MH⁺].

Anal calc for C₁₄H₂₃N₃O₃·1/2H₂O: C, 57.9; H, 8.34; N, 14.48. Found: C, 57.88; H, 8.21; N, 14.48.

• *1-{[N-(Benzylloxycarbonyl)glycyl]amino}cyclopropane-1-carbonitrile 1b*

Prepared in 20% yield according to the general procedure, mp 146 °C (C₆H₁₂/EtOAc 2:1).

¹H NMR (CDCl₃): 7.3–7.2 (m, 6H), 5.60 (br s, 1H), 4.95 (s, 2H), 3.7 (d, 2H), 1.35 (m, 2H), 1.12 (m, 2H).

^{13}C NMR (CDCl_3): 170.4, 156.8, 136.0, 128.5, 128.2, 127.9, 120.0, 67.2, 44.3, 20.2, 16.5.

MS: m/z (%) 291 (100) $[\text{MNH}_4^+]$, 274 (17) $[\text{MH}^+]$, 108 (22).

Anal calc for $\text{C}_{14}\text{H}_{15}\text{N}_3\text{O}_3 \cdot 1/2\text{H}_2\text{O}$: C, 59.55; H, 5.72; N, 14.89. Found: C, 60.27; H, 5.77; N, 14.49.

• 1- $\{[N-(\text{Benzyloxycarbonyl})\text{-}L\text{-phenylalanyl}]\text{amino}\}$ -cyclopropane-1-carbonitrile **3b**

Obtained in 33% yield according to the general procedure, mp 144 °C (EtOAc).

$[\alpha]_D^{20} = -3$ ($c = 0.2$, CH_2Cl_2).

^1H NMR (CDCl_3): 7.26–7.05 (m, 10H), 6.82 (s, 1H), 5.62 (d, $J = 6.2$ Hz, 1H), 4.99 (s, 2H), 4.31 (m, 1H), 3.00 (m, 2H), 1.48 (m, 2H), 0.95 (m, 2H).

^{13}C NMR (CDCl_3): 172.3, 156.3, 135.8, 129.3, 128.8, 128.6, 128.3, 127.9, 126.2, 119.6, 67.2, 55.9, 20.1, 16.5.

MS: m/z (%) 381 (100) $[\text{MNH}_4^+]$, 364 (55) $[\text{MH}^+]$, 327 (20), 273 (50), 230 (45).

Anal calc for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_3$: C, 69.39; H, 5.83; N, 11.57. Found: C, 69.12; H, 5.56; N, 11.89.

• 1- $\{[N-(\text{Benzyloxycarbonyl})\text{-}L\text{-valyl}]\text{amino}\}$ -cyclopropane-1-carbonitrile **4b**

Obtained in 33% yield, mp 201 °C (EtOAc).

$[\alpha]_D^{20} = -18$ ($c = 1.25$, CH_2Cl_2).

^1H NMR (CD_3OD): 7.33 (m, 5H), 5.15 (s, 2H), 3.90 (m, 1H), 2.05 (m, 1H), 1.55 (m, 2H), 1.25 (m, 2H).

^{13}C NMR (CD_3OD): 174.0, 157.4, 136.5, 128.8, 128.5, 128.2, 120.2, 67.3, 60.2, 31.6, 20.4, 19.2, 18.0, 16.6, 16.2.

MS: m/z (%) 333 (80) $[\text{MNH}_4^+]$, 316 (100) $[\text{MH}^+]$, 182 (15).

Anal calc for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_3 \cdot \text{H}_2\text{O}$: C, 61.23; H, 6.95; N, 12.61. Found: C, 61.01; H, 6.41; N, 12.65.

• 1- $\{[N-(\text{Benzyloxycarbonyl})\text{glycyl}]\text{amino}\}$ -cyclopropane-1-carboxylic acid methyl ester **1c**

Obtained as an amorphous solid in 70% yield according to the general procedure.

^1H NMR (CDCl_3): 7.25 (s, 5H), 6.95 (s, 1H), 5.65 (br s, 1H), 5.05 (s, 2H), 3.80 (d, $J = 5.7$ Hz, 1H), 3.65 (s, 3H), 1.5 (m, 2H), 1.05 (m, 2H).

^{13}C NMR (CDCl_3): 172.6, 170.5, 156, 136.0, 128.5, 128.2, 127.9, 67.1, 52.6, 44.5, 33.3, 17.5.

MS: m/z (%) 324 (100) $[\text{MNH}_4^+]$, 307 (60) $[\text{MH}^+]$, 279 (30), 241 (30), 180 (40).

Anal calc for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_5$: C, 58.80; H, 5.93; N, 9.16. Found: C, 58.53; H, 6.35; N, 8.76.

• 1- $\{[N-(\text{Benzyloxycarbonyl})\text{-}L\text{-phenylalanyl}]\text{amino}\}$ -cyclopropane-1-carboxylic acid methyl ester **3c**

Obtained in 60% yield according to the general procedure, mp 144 °C ($\text{C}_6\text{H}_{12}/\text{EtOAc}$ 2:1).

$[\alpha]_D^{20} = -5$ ($c = 0.1$, CH_2Cl_2).

^1H NMR (acetone- d_6): 7.95 (s, 1H), 7.31 (m, 10H), 6.45 (d, $J = 8.5$ Hz, 1H), 5.06 (br s, 2H), 4.44 (m, 1H), 3.65 (s, 3H), 3.25 (dd, $J = 13.8$; 5.5 Hz, 1H), 2.99 (dd, $J = 13.8$; 8.6 Hz, 1H), 1.45 (m, 2H), 1.05 (m, 2H).

^{13}C NMR (acetone- d_6): 173.8, 173.4, 157.2, 139.1, 138.8, 130.8–127.8, 67.2, 57.5, 53.0, 39.5, 18.2, 18.0.

MS: m/z (%) 414 (25) $[\text{MNH}_4^+]$, 397 (100) $[\text{MH}^+]$, 353 (10), 263 (50), 225 (25).

Anal calc for $\text{C}_{22}\text{H}_{24}\text{N}_3\text{O}_5 \cdot \text{H}_2\text{O}$: C, 65.16; H, 6.22; N, 6.91. Found: C, 64.76; H, 6.06; N, 6.72.

• 1- $\{[N-(\text{Benzyloxycarbonyl})\text{-}L\text{-valyl}]\text{amino}\}$ -cyclopropane-1-carboxylic acid methyl ester **4c**

Obtained as an amorphous solid in 86% yield according to the general procedure.

$[\alpha]_D^{20} = -8$ ($c = 0.2$, CH_2Cl_2).

^1H NMR (CDCl_3): 7.3 (s, 5H), 6.65 (s, 1H), 5.40 (d, $J = 8.9$ Hz), 5.05 (s, 2H), 3.90 (dd, $J = 8.9$, 8.5 Hz), 3.55 (s, 3H), 2.05 (m, 1H), 1.50 (m, 2H), 1.05 (m, 2H), 0.94 (d, $J = 6.2$ Hz, 3H), 0.90 (d, $J = 7.3$ Hz, 3H).

^{13}C NMR (CDCl_3): 172.6, 170.5, 156, 136.0, 128.5, 128.2, 127.9, 67.1, 52.6, 44.5, 33.3, 17.5.

MS: m/z (%) 366 (90) $[\text{MNH}_4^+]$, 349 (100) $[\text{MH}^+]$, 215 (20).

Anal calc for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5$: C, 62.04; H, 6.95; N, 8.04. Found: C, 61.98; H, 6.85; N, 8.33.

References

- For two recent reviews:
 - Kodama H, Shimohigashi Y, *J Synth Org Chem Jpn* (1994) 52, 180
 - Alami A, Calmes M, Daunis J, Jacquier R, *Bull Soc Chim Fr* (1993) 130, 5
- Barone V, Fraternali F, Cristinziano PL, Lelj F, Rosa A, *Biopolymers* (1988) 27, 1673
 - Benedetti E, Di Blasio B, Pavone V, Pedone C, Santini A, Crisma M, Valle G, Toniolo C, *Biopolymers* (1989) 28, 175
 - Toniolo C, *Int J Peptide Protein Res* (1990) 35, 287
- Suckling CJ, *Angew Chem Int Ed Engl* (1988) 27, 537
- Stammer CH, *Tetrahedron* (1990) 46, 2231 and references cited therein
 - Kemp A, Tedford MC, Suckling CJ, *Bioorg Med Chem Lett* (1991) 1, 557
 - Kemp A, Ner SK, Rees L, Suckling CJ, Tedford MC, Bell AR, Wriggleworth R, *J Chem Soc Perkin Trans 2* (1993) 741
 - Bailie JR, Walker B, Nelson J, Murphy RF, *Int J Peptide Protein Res* (1994) 43, 225
 - Husbands S, Suckling CA, Suckling CJ, *Tetrahedron* (1994) 50, 9729
 - Fink CA, Qiao Y, Berry CJ, Sakane Y, Ghai R, Trapani AJ, *J Med Chem* (1995) 38, 5023
 - Breveglieri A, Guerrini R, Salvadori S, Bianchi C, Bryant SD, Attila M, Lazarus LH, *J Med Chem* (1996) 39, 773
- One exception is the synthesis of an Acc-containing protein achieved using site-directed mutagenesis: Ellman JA, Mendel D, Schultz PG, *Science* (1992) 255, 197
- Stewart FHC, *Aust J Chem* (1981) 34, 2431
- Guillaume D, Aitken DJ, Husson HP, *Synlett* (1991) 10, 747
- Guillaume D, Brum-Bousquet M, Aitken DJ, Husson HP, *Bull Soc Chim Fr* (1994) 131, 391
- Bossler HG, Seebach D, *Helv Chim Acta* (1994) 77, 1124
- Kawashiro K, Yoshida H, Morito S, *Chem Lett* (1974), 1
- Seebach D, *Angew Chem Int Ed Engl* (1988) 27, 1624
 - Seebach D, Bossler HG, Gründler S, Shoda S, Wenger R, *Helv Chim Acta* (1991) 74, 197
 - Gerber C, Seebach D, *Helv Chim Acta* (1991) 74, 1373
 - Pietzonka T, Seebach D, *Angew Chem Int Ed Engl* (1992) 31, 1481
 - Seebach D, Beck AK, Bossler HG, Gerber C, Ko SY, Murtiashaw CW, Naef R, Shoda S, Thaler A, Krieger M, Wenger R, *Helv Chim Acta* (1993) 76, 1564

- f) Bossler HG, Waldmeier P, Seebach D, *Angew Chem Int Ed Engl* (1994) 33, 439
- 12 Grangier G, Aitken DJ, Guillaume D, Tomas A, Viossat B, Husson HP, *J Heterocycl Chem* (1994) 31, 1707
- 13 a) O'Donnell MJ, Bruder WA, Eckrich TM, Shullenger DF, Staten GS, *Synthesis* (1984) 127
b) Salaün J, Marguerite J, Karbour B, *J Org Chem* (1990) 55, 4276
- 14 Alexakis A, Frutos JC, Mutti S, Mangeney P, *J Org Chem* (1994) 59, 3326
- 15 a) Larock RC, In *Comprehensive Organic Transformations*, VCH, New York, 1989
The acid derivative formed sometimes during the reaction work up by hydrolysis of the ester group can easily regenerate the initial ester ($\text{SOCl}_2/\text{MeOH}$)
b) Greenlee WJ, *Tetrahedron Lett* (1982) 23, 3995
c) Mojsos S, Mitchell AR, Merrifield RB, *J Org Chem* (1980) 45, 555
d) Liberek B, *Chem Ind* (1961) 987
- 16 *Principles of Peptide Synthesis*, 2nd Edition, M Bodansky, Springer Lab, 1993
- 17 Rich DH, In *Protease inhibitors* (Barett AJ, Salvesen G, eds), Elsevier Science Publishers, Amsterdam, 1986, 13-178
- 18 Coggins JR, Kray W, Shaw E, *Biochem J* (1974) 138, 579
- 19 McMath AR, Guillaume D, Husson HP, manuscript in preparation.